Literature DB >> 9074540

Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease.

K Fukuchi1, K Hashikawa, Y Seike, H Moriwaki, N Oku, M Ishida, M Fujita, T Uehara, H Tanabe, H Kusuoka, T Nishimura.   

Abstract

UNLABELLED: This study was designed to elucidate a central type of benzodiazepine (Bz) receptor distribution in patients with Alzheimer's disease using SPECT with [123I]iomazenil (IMZ).
METHODS: Eight patients with probable Alzheimer's disease were studied. Benzodiazepine receptor imaging was performed 15 min (early) and 180 min (delayed) after intravenous administration of 167 MBq IMZ, sequentially, using hexamethylpropylene amine oxime (HMPAO) SPECT to evaluate regional cerebral perfusion.
RESULTS: Early IMZ-SPECT depicted areas of reduced uptake in sites of decreased cerebral blood flow (CBF), but each area of decreased uptake was extended wider than the area of hypoperfusion. Delayed IMZ-SPECT images demonstrated a similar pattern of decreased area of CBF; the affected region in Bz receptor bindings, however, was clearer and broader compared with that in either HMPAO-SPECT or early IMZ-SPECT. In comparison with the uptakes for the normal cerebral hemisphere (ratio to the contralateral cerebellum) in patients with unilateral cerebral infarction as a control group (n = 4), the patients with Alzheimer's disease showed distinctive bilateral frontal or parietal defects (p < 0.05).
CONCLUSION: Brain SPECT using IMZ may be more sensitive than CBF images in patients with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074540

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Parvalbumin-Positive Neuron Loss and Amyloid-β Deposits in the Frontal Cortex of Alzheimer's Disease-Related Mice.

Authors:  Farhan Ali; Stephanie L Baringer; Arianna Neal; Esther Y Choi; Alex C Kwan
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

2.  SPECT imaging of GABA(A)/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment.

Authors:  Sabina Pappatà; Andrea Varrone; Caterina Vicidomini; Graziella Milan; Caterina De Falco; Valeria Sansone; Alessandro Iavarone; Marco Comerci; Elisa Loré; Maria Rosaria Panico; Mario Quarantelli; Alfredo Postiglione; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

Review 3.  Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.

Authors:  Karan Govindpani; Beatriz Calvo-Flores Guzmán; Chitra Vinnakota; Henry J Waldvogel; Richard L Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2017-08-21       Impact factor: 5.923

Review 4.  Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer's disease.

Authors:  Ramsey Najm; Emily A Jones; Yadong Huang
Journal:  Mol Neurodegener       Date:  2019-06-11       Impact factor: 14.195

Review 5.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.